Yonjin Venture
VC Fund
Cambridge, United States
Yonjin Venture is an investment firm specializing in investing in early and mid-stage life science companies.It focuses on the innovative technologies in therapeutics, diagnostics, and medical devices. The firm is a sub-organization of Yongjin Group and the sister firm of Yonghua Capital.The Cambridge, Massachusetts-based firm was establishedin 2018.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Yonjin Venture invests in
Stages Yonjin Venture invests in
Countries Yonjin Venture invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 13 (52%)
- Biotechnology 13 (52%)
- Medical 7 (28%)
- Medical Device 5 (20%)
- Therapeutics 4 (16%)
Stage
- Series A 7 (28%)
- Series B 6 (24%)
- Series C 4 (16%)
- Series D 2 (8%)
- Funding Round 2 (8%)
Country
- United States 14 (56%)
- China 1 (4%)
- Israel 1 (4%)
- Belgium 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Chong Wang
Executive Director
|
Executive Director | Total investments: 0 | Find email | |
Daguan Wang
Managing Director
|
Managing Director | Total investments: 4 | Find email | |
|
Fanbo Meng
Executive Director
|
Executive Director | Total investments: 0 | Find email | |
|
Gary Yang
Partner
|
Partner | Total investments: 0 | Find email | |
Qiong Ye
Vice President
|
Vice President | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rapafusyn Pharmaceuticals
|
Rapafusyn Pharmaceuticals licenses technology related to a novel class of natural product-like macrocycle. The company develops novel pharmaceuticals to treat patients having diseases and fulfill other unmet medical needs. | $16M / Series A / Sep 04, 2025 | |
HistoSonics
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | Private Equity / Aug 07, 2025 | |
TECLens
|
TECLens is creating a crosslinking technology that may accurately fix vision issues in healthy eyes as well as treat keratoconus. It provides patients with presbyopia with the ability to regain their ability to read at a distance, controls children's progressive myopia, corrects adult vision problems like hyperopia and low-order myopia, andmore. | $9.3M / Series A / Feb 11, 2025 | |
CSA Medical
|
CSA Medical provides cryotherapy systems. It offers CryoSpray Ablation system, which enables the physicians to freeze, destroy, and remove unwanted tissues, as well as transports liquid nitrogen that is passed through a standard endoscope. CSA Medical was formerly known as Crymed Technologies and changed its name to CSA Medical in April 2006.Thecompany was incorporated in 1993 and is based in Lutherville Timonium, Maryland. | $53M / Series D / Sep 09, 2024 | |
|
HistoSonics
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $102M / Series D / Aug 15, 2024 | |
EvolveImmune Therapeutics
|
EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases. | $37.4M / Venture - Series Unknown / Nov 16, 2023 | |
|
HistoSonics
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $85M / Convertible Note / Dec 13, 2022 | |
Intressa Vascular
|
Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection. | $12M / Oct 25, 2022 | |
Bluejay Therapeutics
|
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate offunctional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients. | $41M / Series B / Aug 16, 2022 | |
Regenacy Pharmaceuticals
|
Regenacy Pharmaceuticals they give services to treat diabetic and other peripheral neuropathies. | $9.3M / Series B / Aug 15, 2022 | |
| See all 25 investments → | |||
Co-Investors
Johnson & Johnson Innovation
5 deals together
3E Bioventures
4 deals together
Cobro Ventures
4 deals together
Lumira Ventures
4 deals together
State of Wisconsin Investment Board
4 deals together
Taiwania Capital Management Corporation
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Yonjin Venture invest in?
Yonjin Venture invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Yonjin Venture?
Public channels for Yonjin Venture include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Yonjin Venture?
The team at Yonjin Venture includes Chong Wang (Executive Director), Daguan Wang (Managing Director) and Fanbo Meng (Executive Director), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
